Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score by Hering, Flavio Luis Ortiz et al.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
ABSTRACT
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
INTRODUCTION
Adenocarcinoma of the prostate is one of
the most common malignancies in men and
one of the main causes of cancer death.1, 2 In
spite of its high incidence, prostate cancer has
a very heterogeneous biological behavior, and
therefore it is very difficult to define its evolu-
tion.3 The prognosis of these tumors depends
on some parameters such as the TNM stag-
ing, the histological differentiation, and oth-
ers. Today, the discovery of genetic abnormali-
ties has an important role in defining the prog-
nosis of cancer.2
Among the most important regulators of
apoptosis and programmed cell death are bcl-
2 and its related proteins. The bcl-2 gene was
first discovered because of its involvement in
the t(14, 18) chromosomal translocations
commonly found in non-Hodgkin’s follicular
B cell lymphomas.1 The protein encoded by
this gene is a potent blocker of apoptosis and
resides primarily in the outer mitochondrial
membrane, nuclear envelope, and parts of the
endoplasmic reticulum.4-6
The bcl-2 gene product regulates pro-
grammed cell death7-9 and a number of stud-
ies suggest that bcl-2 is involved in the se-
lection and maintenance of long-living cells,
rescuing them from apoptotic cell death,
and leading to their accumulation in the G1
phase of the cell cycle.5 Abnormalities in the
expression of apoptosis suppressing gene
bcl-2 are frequently detected in many epi-
thelial neoplasms.8, 10 The prognostic signifi-
cance of the abnormal expression of the bcI-
2 protein has been analyzed, particularly in
breast cancer, and the results suggest that
bcl-2 protein expression may also have prog-
nostic significance.7, 11
Overproduction of the bcl-2 protein oc-
curs in a wide variety of human cancers and
presumably contributes to neoplastic expan-
sion by prolonging cell survival through sup-
pression of the physiological cell turnover
mechanisms that normally maintain a
homeostatic balance between cell production
during cell division and cell loss through pro-
grammed cell death.2, 3, 10
The bcl-2 is a 25KD oncoprotein ex-
pressed in hormone-sensitive epithelium, in-
cluding the glandular prostatic epithelium.
Recent studies have shown the importance of
studying this protein in prostate cancer to try
to prevent disease development. bcl-2 is ex-
pressed in several epithelial tissues,2, 3, 9, 12, 13
including the prostatic epithelium.2, 3 It is ex-
pressed in normal prostatic epithelium, in
prostatic ducts and in prostatic tumors, as re-
ported previously.13 The expression is more
common in tumors that exhibit malignant
features, such as the invasive growth type and
high proliferation rate of cancer cells, although
a previous analysis of a small cohort of cases
has suggested no significant relationship be-
tween histological differentiation and the ex-
pression of bcl-2 protein.13
Immunohistochemical analysis of bcl-2
protein levels in prostate tumors has revealed
a correlation between the presence of bcI-2
protein and resistance to anti-androgen
therapy.2 Taken together, these observations
suggest that elevated levels of bcl-2 protein
may contribute to the progression of prostate
cancers to a metastatic and hormone-insensi-
tive state characterized by poor responses to
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CONTEXT: Multiple genetic and epigenetic factors
have been implicated in the oncogenesis and
progression of prostate cancer. The major diffi-
culty is in that the clinical management stems
from the reality that reliable and accurate prog-
nostic biomarkers are not available and that ef-
fective treatment regimens forming hormone-re-
sistant prostate cancers are yet to be developed.
Among the most important regulators of
apoptosis and programmed cell death is the bcl-
2 gene and its related proteins. Elevated levels
of bcl-2 protein may contribute to the progres-
sion of prostate cancers to a metastatic and hor-
mone-insensitive state characterized by poor re-
sponses to chemotherapy.
OBJECTIVE: To characterize the expression of bcl-2
proteins as a prognostic factor in humans.
DESIGN: A retrospective approach.
SETTING: Urology section, Federal University of São
Paulo.
DIAGNOSTIC TEST USED: Immunohistochemical
analysis using bcl-2 protein antibody and nor-
mal staining by hematoxylin-eosin.
MAIN MEASUREMENTS: Prognostic relations and
protein expression were evaluated considering
the total sample (28) divided into two groups,
high (8 to 10) and low (2 to 4), separated ac-
cording to the histological differentiation grade
(Gleason score) with 10 and 18 samples, re-
spectively.
RESULTS: The differentiation of grade into two groups
separated according to the Gleason score in low
and high types presented different bcl-2 expres-
sion (P < 0.001).
CONCLUSION: The higher frequency of bcl-2
immunostaining in tumor samples was observed
in association with more advanced Gleason
scores and suggests that an increase in the ratio
of this anti-apoptotic protein often occurs during
progression of prostate cancers.
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chemotherapy. Using an immunohistochemi-
cal approach, Krajewska et al. (1996)1 char-
acterized the expression of the bcl-2 family of
genes in human prostate cancers and corre-
lated these results with the Gleason grade. The
higher levels of bcl-2 immunostaining gener-
ally seen here in association with more ad-
vanced Gleason grade and metastatic disease
suggest that an increase in the ratio of these
anti-apoptotic proteins often occurs during
progression of prostate cancers.1 The inten-
sity of bcl-2 immunostaining and the percent-
age of immunopositive cells are generally
higher in the more advanced tumors, largely
accounting for the higher composite scores.1
The present analysis was done to test the
possible prognostic value of abnormal expres-
sion of the bcl-2 protein in prostatic adeno-
carcinoma associated with the Gleason score,
which was divided into two extreme groups:
a low score (2-4) and a high score (8-10). This
was done with no use of androgen ablation.
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METHODS
We randomly selected 28 patients with a
diagnosis of clinically localized adenocarci-
noma of the prostate, who underwent radical
prostatectomy and were divided into two
groups, according to the Gleason score: a) 18
patients with Gleason score 8 to 10, and b)
10 patients with Gleason score 2 to 4. These
patients had not been submitted to any kind
of previous hormonal treatment.
Histological and immunohistochemistry
methods. First, 5 µm-thick sections were cut
from the paraffin-embedded tumor specimens
and stained with HE. The samples were ex-
amined for the histological prognostic factors
by one investigator, who was unaware of the
clinical data. Tumors were graded according
to Gleason’s grading system. All slides were
reviewed and a Gleason score was determined
by adding the numbers for the two most pre-
dominant patterns.
For the immunohistochemical demon-
stration of the bcl-2 protein, 5-µm sections
from the primary prostatic carcinomas were
deparaffinized, rehydrated and washed for
5 minutes with PBS. Thereafter the sections
were rinsed in distilled water and heated in
a microwave oven for 15 to 45 minutes in
0.01 M citrate buffer (pH 6.0). After mi-
crowave oven heating, the slides were rinsed
in Tris-buffered saline (pH 7.4). Endog-
enous peroxide was blocked by 3% hydro-
gen peroxide for 5 minutes, followed by
washing for five minutes with PBS. The tis-
sue sections were incubated with the
monoclonal anti-bcl-2 protein (Dako Corp.,
CA) antibody diluted at 1:400 in PBS. Sec-
tions were washed twice for 5 minutes with
PBS, and incubated for 20 minutes with AB
Duet complex (Dako Corp., CA) diluted at
1:200 in PBS for 30 minutes. Sections were
washed twice for five minutes with PBS,
developed with diaminobenzidine
tetrahydrochloride substrate (Sigma),
slightly counterstained with hematoxylin,
dehydrated, cleared and mounted.
Scoring of bcl-2 expression. All slides were
evaluated for immunostaining in a blind fash-
ion, without any knowledge of the clinical
outcome or other clinical and pathological
data. The proportional pattern and intensity
of immunostaining for bcl-2 were evaluated.
Statistical methods. The comparison of
proportions of immunostaining of the
oncoprotein bcl-2 between the two different
Gleason score groups was done using the
Mann-Whitney test.
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RESULTS
A total of 28 cases of prostate adenocarci-
noma, consisting of 10 cases classified as low
Gleason score (2, 3, 4) and 18 cases of high
Gleason score (8, 9, 10), were examined in
this study. The Gleason score and frequency
of cells immunostained for bcl-2 in each group
are summarized in Tables 1 and 2.
Of the 18 cases of high Gleason score
(Table 1) 15 had a staining frequency of 70%
or more (Figure 1a). Considering the low
Gleason group (Table 2), 9 cases of a sample
of 10 presented a staining of less than 30%
of the cells expressing the bcl-2 protein (Fig-
ure 1b). One patient had an 80% staining
frequency in this group, probably due to
other factors of poor prognosis simultane-
ous to bcl-2 expression and not identified in
this approach. This difference between the
two groups was statistically significant (P <
0.001) indicating an over-expression in pa-
tients of the group presenting a higher
Gleason score.
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DISCUSSION
Prostate cancer, like most other solid
tumors, represents a very heterogeneous en-
tity. Most prostate cancers, at the time of
clinical diagnosis, present themselves as mix-
tures of androgen-dependent and androgen-
independent cells.2 Most prostate cancers re-
spond initially to androgen ablation since the
population of androgen-dependent cells un-
dergoes rapid apoptosis upon androgen with-
drawal. However, androgen ablation rarely
cures patients, most of whom will experience
recurrence due to takeover of the tumor mass
by androgen-independent tumor cells as well
as the emergence of apoptosis-resistant clones
as a result of further genetic alterations such
as bcl-2 amplification.14
Proteins encoded by the bcl-2 family of
genes are important regulators of pro-
grammed cell death and apoptosis.3 Altera-
tions in the expression of these apoptosis-
regulating genes can contribute to the ori-
Table 1. Gleason score and bcl-2
staining frequency in patients with
adenocarcinoma of the prostate
High Gleason Score
Patient Gleason bcl-2 staining
       (%)
1 8 70
2 8 80
3 9 65
4 8 35
5 9 70
6 8 75
7 9 85
8 10 95
9 10 90
10 9 85
11 8 90
12 8 70
13 8 35
14 8 75
15 8 85
16 8 90
17 9 95
18 9 75
Table 2. Gleason score and bcl-2
staining frequency in patients with
adenocarcinoma of the prostate
Low Gleason Score
Patient Gleason bcl-2 staining
       (%)
1 4 10
2 4 20
3 4 30
4 4 25
5 3 15
6 4 10
7 4 10
8 4 15
9 4 15
10 4 80
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gins of cancer, as well as adverse tumor re-
sponses to chemotherapy and radiotherapy.1
Apoptosis has a fundamental role in pro-
moting the tumorigenesis process.3 Usually
apoptosis is an active non-inflammatory proc-
ess of cell death that maintains homeostasis.
When some abnormalities occur, the process
is facilitated.1
bcI-2 is a potent apoptosis-suppressing
protein.15 This protein has a well-known role
in developing some lymphomas and perhaps
in the progression of breast and prostate can-
cer, by maintaining the longevity of cells via
suppressing their programmed death.2, 16 Its
expression is more common in tumors with
invasive behavior, high proliferation rate and
abnormal cell differentiation features.2
We observed a significant difference in
the bcl-2 protein expression between the
two groups of patients with adenocarcinoma
of the prostate. This variation could be due
to different characteristics of the disease evo-
lution. Westin et al. (1995),17 studying bi-
opsies of prostate cancer observed that bcl-
2 increased one week after castration and
after androgen ablation before tumor
regrowth. Tsuji et al. (1998)1 verified that
bcl-2 expression increases with androgen
ablation and the proliferative activity of
tumor cells is significantly reduced. The bcl-
2 expression probably exerts a role in the
longevity of tumor cells submitted to hor-
monal therapy. They also observed that mib-
1 expression is related to the different grades
of tumor cells, but this does not occur with
bcl-2. This data in the literature only con-
siders the expression of these genes after en-
docrine therapy and this could be an im-
portant factor for changing the results.
Colombel et al. (1993),13 studying bcl-2
expression in hormone-resistant prostatic ad-
enocarcinoma, did not correlate the expres-
sion of this oncogene with tumor histological
differentiation. This difference must probably
be due to previous hormone-deprivation treat-
ment, which could alter the interpretation of
the histological grade and also the expression
of the gene.
There is evidence that some members of
the bcl-2/cd9 family regulate programmed cell
death in an evolving manner concerning pros-
tate cancer and an over-expression of bcl-2 is
associated with progression and an androgen-
resistant phenotype.19
Krajewska et al. (1996),1 studying the ex-
pression of the bcl-2 family in prostate cancer
(genes bax, bcl-x and mcl-1) correlated to the
Gleason score, verified that the stage progres-
sion and the score increase are positively re-
lated to the increase in the expression of these
genes. The over-expression of bcl-2 can also
give a replication capacity to the hormone-
resistant prostatic tumor cells,20 associated
with the poor prognosis of this neoplasm.2
Grossfeld et al. (1998)19 observed that, in
patients with increased Ki-67, p53 and bcl-2
expression, the recurrence rate for prostate can-
cer after surgery or radiotherapy was higher.
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CONCLUSION
In conclusion, the over-expression of bcl-
2 is significantly higher in patients with an ini-
tially elevated Gleason score (8, 9 and 10). Fur-
ther studies, including intermediate Gleason
scores (5, 6 and 7) could provide more evidence
for the role of this protein in the development
and progression of prostate cancer.
Figure 1. Immunohistochemical analysis of bcl-2 protein in prostate cancers. Representative photomicrographs are shown of tissue
sections derived from primary prostate cancers that were immunostained using antibodies specific for bcl-2. Antibody detection was
accomplished using a diaminobenzidine colorimetric method (brown) and nuclei were counterstained with hematoxylin (blue).
a) High grade (Gleason 8-10) tumor with a bcl-2 positive high immunoreactivity (40X).
b) Low grade (Gleason 2-4) tumor illustrating an example of a mostly bcl-2 negative expression (100X).
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CONTEXTO: Diversos fatores genéticos e
ambientais têm sido relacionados à
oncogênese e progressão do câncer de
próstata. A principal dificuldade na conduta
clínica frente a esses tumores consiste no fato
de não existirem marcadores prognósticos
precisos, e que tratamentos eficazes dos
tumores hormônio-resistentes não estão ainda
disponíveis. Entre os reguladores mais
importantes para avaliar a taxa de apoptose,
destaca-se a expressão da proteína bcl-2. Os
níveis elevados dessa proteína podem
contribuir na progressão dos tumores
prostáticos para um estado metastático e/ou
hormônio independente, que caracte-
risticamente não apresenta resposta satis-
fatória ao tratamento quimioterápico.
OBJETIVO: Investigar a expressão da proteína
bcl-2 como fator prognóstico em portadores
de tumores prostáticos.
TIPO DE ESTUDO: Estudo retrospectivo.
LOCAL: Disciplina de Urologia da Universidade
Federal de São Paulo.
TESTE DIAGNÓSTICO: Exame anato-
mopatológico convencional por hema-
toxilina-eosina (HE) e imunohistoquímico.
VARIÁVEIS ESTUDADAS: Expressão prog-
nóstica da proteína bcl-2, por técnica
imunohistoquímica em portadores de adeno-
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RESUMO
carcinoma da próstata submetidos a
prostatectomia radical.
AMOSTRA: 28 amostras de tumores de próstata
fixadas em parafina, provenientes de pacientes
submetidos à prostatectomia radical sem
ablação androgênica prévia, avaliadas por HE
e por imunohistoquímica para a carac-
terização da expressão da proteína bcl-2. A
expressão foi correlacionada ao grau de
diferenciação do tumor, dividindo-se os
tumores em dois grupos, segundo o escore
de Gleason, em baixo (escore 2 a 4), e alto
grau (8 a 10), sendo que os grupos foram
divididos em 18 e 10 pacientes, respec-
tivamente.
RESULTADOS: Observou-se associação
estatisticamente significativa (P < 0, 001) en-
tre expressão elevada da proteína e os casos
que apresentavam um escore de Gleason mais
elevado (83, 3%), enquanto que no grupo de
escore de baixo grau não foi detectada
expressão da bcl-2 em 90% das amostras.
CONCLUSÕES: O aumento na expressão da
proteína bcl-2 em tumores de próstata com
escore de Gleason elevado pode estar
associado à progressão do adenocarcinoma de
próstata.
PALAVRAS-CHAVE: bcl-2. Próstata. Adenocar-
cinoma da próstata. Apoptose.
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